Publication:


abstract

Background: sildenafil has been demonstrated as effective for the treatment of pulmonary arterial hypertension (PAH). The purpose of this study was to investigate the occurrence of clinical events after sildenafil monotreatment as a first-line therapy in patients with PAH over a long-term observation period. Methods and Results: Sildenafil was administered as a first-line drug to 46 patients with PAH (including 24 patients with idiopathic PAH) during 2003-2010. We investigated subsequent clinical events such as the addition of epoprostenol, hospitalization for right-side heart failure, and death. All the hemodynamic parameters and the 6-min walk distance improved significantly in the enrolled patients as a whole receiving sildenafil treatment; 15 (33%) of the 46 patients required the addition of epoprostenol during follow-up. Kaplan-Meier analysis demonstrated that more than 60% of the patients receiving first-line sildenafil treatment did not require the addition of epoprostenol for a 5-year period. Furthermore, the 5-year survival rate after first-line sildenafil treatment was 81%. Finally, more than 75% of the enrolled patients did not reach the composite endpoint of hospitalization for right-side heart failure and death for a 5-year period. Conclusions: This study describes the long-term outcome of patients with PAH receiving sildenafil monotreatment as a first-line therapy and suggests that it is a promising therapeutic strategy. (Circ J 2012; 76: 1245-1252).

Related Articles
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Ann Intern Med. 2008
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, et al. Ann Intern Med. 2008 Oct 21; 149(8):521-30.
The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.
Hypertens Res. 2009
The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.
Xu XQ, Jing ZC, Zhang JH, Wu Y, Wang Y, Jiang X, Wang ZX, Sun YG, Pu JL, Yang YJ. Hypertens Res. 2009 Oct; 32(10):911-5. Epub 2009 Jul 31.
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
J Am Coll Cardiol. 2003
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, et al. J Am Coll Cardiol. 2003 Jul 2; 42(1):158-64.
Review Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Health Technol Assess. 2009
Review Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D. Health Technol Assess. 2009 Oct; 13(49):1-320.
Review Evidence-based pharmacologic management of pulmonary arterial hypertension.
Clin Ther. 2007
Review Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N, Seybert A, Mathier MA. Clin Ther. 2007 Oct; 29(10):2134-53.